Overcoming obstacles to repurposing for neurodegenerative disease

Diana W. Shineman*, John Alam, Margaret Anderson, Sandra E. Black, Aaron J. Carman, Jeffrey L. Cummings, Penny A. Dacks, Joel T. Dudley, Donald E. Frail, Allan Green, Rachel F. Lane, Debra Lappin, Tanya Simuni, Richard G. Stefanacci, Todd Sherer, Howard M. Fillit

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.

Original languageEnglish (US)
Pages (from-to)512-518
Number of pages7
JournalAnnals of clinical and translational neurology
Issue number7
StatePublished - Jul 2014

ASJC Scopus subject areas

  • Clinical Neurology
  • General Neuroscience


Dive into the research topics of 'Overcoming obstacles to repurposing for neurodegenerative disease'. Together they form a unique fingerprint.

Cite this